Authors recommend that dermatologists perform a total-body skin examination even when a patient is referred for a suspicious lesion
WEDNESDAY, Aug. 11, 2021 (HealthDay News) — Dermatologist-performed total body skin examinations (TBSEs) identify numerous cutaneous malignancies that might otherwise remain undiagnosed, according to a study recently published in the International Journal of Women’s Dermatology.
Angela Jiang, M.D., from the Henry Ford Health System in Detroit, Michigan, and colleagues assessed dermatology records of 1,010 patients with biopsy-proven melanoma, basal cell carcinoma (BCC), or squamous cell carcinoma (SCC).
The researchers found that of the 1,563 biopsy-proven cutaneous malignancies, 51 percent were first identified by a dermatologist on TBSE, while 48.9 percent were identified by the patient or the referring provider. Of the 797 tumors first identified by dermatologists, 69 percent were BCCs, 28 percent were SCCs, and 3 percent were melanomas. BCCs were significantly more likely to be identified by a dermatologist during a TBSE. However, SCCs were more often identified by patients or their primary care providers. For melanomas, the mean Breslow depth was 0.53 mm for those found on TBSE versus 1.04 mm for those identified by patients or the referring providers.
“Dermatologists need to take the opportunity to look over the patient’s entire body, even when the appointment is just for a suspicious lesion,” a coauthor said in a statement. “And patients need to request one in case the doctor doesn’t suggest it.”
EHR-Enabled QI Intervention Improves Chlamydia, Gonorrhea Screening in Teens
Genetic Screening Can ID Hemoglobinopathy Prevalence
AI Tool Trained on Dermoscopy Images Helps ID Skin Cancer
Urine Cell-Free RNA Shows Promise as Biomarker for Bladder Cancer
Pre-Prostate Biopsy MRI Use Increased From 2017 to 2026
ASTRO Issues Guidance for Use of Radiation Therapy in Bladder Cancer
Higher Intake of Saturated, Animal Fats May Increase Mortality in Prostate Cancer
Adverse Pathological Features Do Not Predict Benefit of Hormone Therapy in Prostate Cancer